Xeris Pharmaceuticals XERS
$16.97 +$0.35 (+2.11%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $17.00 +0.18%
Open$16.61
Prev close$16.62
Day range$16.53 – $17.04
Volume2.86M
Market cap$3.10B
P/E (TTM)–
Dividend yield–
XERS Stock News
Headlines matching Xeris Pharmaceuticals or the XERS ticker, most recent first.
- Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $12
- H.C. Wainwright Remains a Buy on Xeris Pharmaceuticals (XERS)
- H.C. Wainwright Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $10
- Piper Sandler Maintains Xeris Pharmaceuticals(XERS.US) With Hold Rating, Maintains Target Price $8
- Leerink Partners Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $16 Positive
- Barclays Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $12 Positive
- Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Announces Target Price $12
- Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating
- Barclays Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $9
- Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Xeris Pharmaceuticals (XERS)
- H.C. Wainwright Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Maintains Target Price $18
- Oppenheimer Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $21 Positive
- H.C. Wainwright Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $18 Positive
- Craig-Hallum Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $18 Positive
- Barclays Maintains Xeris Pharmaceuticals(XERS.US) With Buy Rating, Raises Target Price to $18 Positive
No comments yet — be the first to weigh in on XERS.
Sign in to join the discussion.